Download FREE Report Sample
Download Free sampleA gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product?protein or polypeptide.
Gene Engineered Subunit Vaccine Market contains market size and forecasts of Gene Engineered Subunit Vaccine in Global, including the following market information:
Global Gene Engineered Subunit Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Gene Engineered Subunit Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Therapeutic Gene Engineered Subunit Vaccine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Gene Engineered Subunit Vaccine include Merck, GSK, Tiantan, Pulike, Greffex, CureVac, Yebio, Sanofi Pasteur SA and Virbac, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Gene Engineered Subunit Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Engineered Subunit Vaccine Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Gene Engineered Subunit Vaccine Market Segment Percentages, by Type, 2021 (%)
Therapeutic Gene Engineered Subunit Vaccine
Preventative Gene Engineered Subunit Vaccine
Global Gene Engineered Subunit Vaccine Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Gene Engineered Subunit Vaccine Market Segment Percentages, by Application, 2021 (%)
Human Use
Veterinary Use
Global Gene Engineered Subunit Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Gene Engineered Subunit Vaccine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Engineered Subunit Vaccine revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Gene Engineered Subunit Vaccine revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
GSK
Tiantan
Pulike
Greffex
CureVac
Yebio
Sanofi Pasteur SA
Virbac
Pfizer Inc.
Walvax Biotechnology
Kontec
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
